Open Access

The impact of the new cooperative medical scheme on financial burden of tuberculosis patients: evidence from six counties in China

  • Li Xiang1,
  • Yao Pan2,
  • Shuangyi Hou3,
  • Hongwei Zhang4,
  • Kaori D. Sato5,
  • Qiang Li6,
  • Jing Wang1Email author and
  • Shenglan Tang5, 7
Infectious Diseases of Poverty20165:8

https://doi.org/10.1186/s40249-015-0094-5

Received: 22 July 2015

Accepted: 30 December 2015

Published: 28 January 2016

Abstract

Background

Tuberculosis (TB) patients in China encounter heavy financial burdens throughout the course of their treatment and it is unclear how China’s health insurance systems affect the alleviation of this burden under the integrated approach. This study aimed to measure reimbursement for TB services under the New Cooperative Medical Scheme (NCMS) in rural China and to evaluate changes in catastrophic health expenditure (CHE) caused by the reimbursement policies.

Methods

Reimbursement data were obtained from routine data systems for the NCMS in Yichang (YC) and Hanzhong (HZ). 1884 TB inpatients reimbursed by NCMS from 2010 to 2012 were included. Household surveys were conducted. A total of 494 TB patients under the NCMS were selected in this paper. 12 Focus Group Discussions (FGDs) were held. We measured the impact of the NCMS by counterfactual analysis, which analyzed the financial burden alleviation. Equity was assessed by Concentration Index (CI), and disaggregated by project sites.

Results

TB inpatients were reimbursed with an effective reimbursement rate of 57.3 %. Average out-of-pocket (OOP) payments for outpatient and inpatient services after diagnosis were 1413 yuan and 430 yuan, and 3572 yuan and 3013 yuan in YC and HZ, respectively. The reimbursement level for TB outpatient care after diagnosis was very low due to a limited outpatient quota. TB patients in HZ incurred higher effective reimbursement rates, but the incidence of CHE remained higher. The reduction of CHE incidence after the NCMS showed no difference statistically (P > 0.05). The severity of CHE was alleviated slightly. CIs after reimbursement were all below zero and their absolute values were higher than those before reimbursement.

Conclusions

Low reimbursement for TB patients could lead to heavy financial burden. Poor TB patients incurred high rates of CHE. The NCMS was found to be a protective factor for CHE, but the impact was modest and the equity of CHE did not improve. The NCMS reimbursement policies should be improved in the future to include a more comprehensive coverage of care. Supplemental programs may be necessary to expand coverage for TB care.

Keywords

NCMSImpactFinancial burdenTB

Multilingual abstracts

Please see Additional file 1 for translations of the abstract into the six official working languages of the United Nations.

Background

China has the second largest burden of tuberculosis (TB) in the world [1], and the “directly observed treatment short course” (DOTS) has been implemented by China’s National TB Program to combat this problem. One smear microscopy and one radiography at first visit, and drugs (6 months for new patients, 8 months if previously treated) are provided free of charge. Despite this, TB patients frequently encounter high costs, often through additional medicines, X-rays and laboratory services, during the course of their treatment [24]. Within the current TB control program, two main approaches have been employed in China: the TB dispensary approach and the integrated approach [5]. In the TB dispensary approach, TB dispensaries [usually departments of the Center for Diseases Control (CDC)] are in charge of TB case detection, diagnosis, treatment, and case management. TB suspects and patients should be reported and referred to TB dispensaries to confirm diagnoses and for treatment by health workers in general hospitals. Only severe or complicated TB cases are further treated in general hospitals. Since 2000, TB prevention and treatment services have transformed from TB dispensaries to designated hospitals in what is called the integrated approach. This design allows TB dispensaries to provide public health care and general hospitals to offer integrated care to TB patients without referral. Other hospitals, including township hospitals, are responsible for referring suspects and patients to the designated hospitals. The integrated model has been considered the better policy option for future TB health reform in China [6]. Prior studies have shown that TB poses a heavy financial burden on patients, especially on those in rural areas [7]. A systematic review conducted in low- and middle-income countries has shown that cost as a percentage of income was particularly high among poor people [8]. With the considerable strain that TB places on its population, protecting TB patients from financial risk is a priority for Chinese policymakers.

Social protection mechanisms were highlighted in the post-2015 Global TB Strategy put forward by The World Health Organization. Health insurance has been considered as a promising way to protect people from financial catastrophe and impoverishment [911]. As for TB control, in the United States, ongoing efforts to control TB were enhanced by bringing millions of currently uninsured Americans into the health care system [12]. Integrating the national TB control program into health insurance schemes is an effective strategy to address challenges in current China [13]. Lack of health insurance is reported to be the key determinant of insufficient TB control in many ways. According to one prospective cohort study, having health insurance helped to improve latent tuberculous infection treatment completion rates in the United States and Canada [14], while a lack of health insurance was found to be responsible for delay in seeking TB care in China [15].

In rural China, TB patients are reimbursed by the New Cooperative Medical Scheme (NCMS). There is a growing body of literature that evaluates the impacts of the NCMS programs on health care utilization and economic burden [1620]; however, they mainly focus on the variation of financial burden on the whole population before and after the NCMS, and few target the impacts of different NCMS reimbursement policies on TB patients specifically. A recent study accessed the effective reimbursement rates of the NCMS among TB patients [21], but it compared TB patients who lived in counties where their schemes covered costs within TB dispensaries and those who did not. Nonetheless, the alleviation of financial burden among TB patients during the entire course of treatment under the integrated approach remains unknown. Moreover, more indicators are needed to assess the impacts of the NCMS on financial burden.

TB patients have several distinctive features in their demand for health care. First, from the clinical viewpoint, only a small proportion of TB patients require treatment via inpatient services. More commonly, TB patients need repeated, long-term outpatient visits. Second, under the current health care system in China, primary care physicians practicing in local clinics or public health centers often do not have the capacity to treat TB patients due to resource and educational constraints. Rather, TB patients are treated at county- or city-level hospitals based on the national TB control policies in China. While the NCMS may be beneficial to meet the unmet health care needs of those in rural China [22], under the integrated approach, its impact on alleviating the financial burden on TB patients in rural populations using diversified indexes and whether this impact is consistent with that of the whole population has yet to be unveiled.

This study focused on TB patients in rural areas of central and western China. We measured TB care reimbursement under the NCMS by using data from patient surveys and the NCMS database. We then assessed the impacts of the NCMS on the financial burden of TB patients by counterfactual analysis and discussed whether the NCMS reimbursement policy reached the goal of equity by using the CI.

Methods

Study setting

The national TB epidemiology survey in 2010 revealed that there existed significant differences in the prevalence of active pulmonary TB across different regions in China. The prevalence of active pulmonary TB in the western region was about 1.7 times that in the central region, and 2.4 times that in the eastern region. Moreover, the prevalence of active pulmonary TB in rural areas was about 1.6 times that in urban areas. Hence, this paper focuses on TB care reimbursement in rural areas of central and western China.

The China National Health and Family Planning Commission (NHFPC)-Bill & Melinda Gates Foundation TB Project has been widely conducted in Yichang (YC) and Hanzhong (HZ). The local governments were able and willing to collaborate in this study. The study was therefore conducted in these two cities.

YC is located in the more developed area of central China and had a GDP per capita of 73,947 yuan in 2011. By contrast, HZ is a relatively low-income area located in western China, which had a GDP per capita of 16,935 yuan in 2011. YC and HZ adopted the integrated approach. Therefore, TB dispensaries were responsible for TB control planning, case reporting, drug procurement and distribution, defaults tracing and health education. One county-level general hospital was designated for integrated care within one county.

Three counties (one from each category of high, middle and low GDP per capita) were purposively selected in each city. As a result, we chose six counties as our study settings: Yidu (YD), Zhijiang (ZJ) and Wufeng (WF) in YC and Chenggu (CG), Mianxian (MX) and Zhenba (ZB) in HZ.

Data collection

Data collection employed a combination of both quantitative and qualitative methods. Quantitative data provided intuitional phenomenon, and qualitative data helped to gain a deeper and more complete understanding of the situation. Quantitative studies included TB patient surveys and reimbursement data from the existing routine data systems for the NCMS. Qualitative studies mainly consisted of a number of Focus Group Discussions (FGDs) and policy documents.

Quantitative study

We adopted probability proportional to size (PPS) sampling to select TB patients. Through this process, we planned to obtain 270 cases per city. Thus, 90 cases per county were needed.

First, townships were randomly selected in each county. We planned to select six townships according to the previous TB case registration list. In ZJ, for example, 370 TB cases were registered in 2012. The sampling interval was 61, and the random number was 29. Accordingly, we listed the sampled patients in a table and the sampled townships were chosen.

Second, 15 TB cases – patients who had completed or stopped treatment during 2012 – were selected in each of the six townships from the TB case registration list. If the sample size of the sampled township was not enough, we supplemented it by choosing from a nearby township. If the sample size was still not enough in this situation, we chose patients who registered in the latter half of 2011 and completed the treatment course.

A standardized questionnaire was designed to conduct patient surveys by face-to-face interviews at local dispensaries or designated hospitals. We collected additional information on personal demographic and socio-economic status (such as education, household income/expenditure), TB related diagnostic and treatment pathway, direct health service expenditures, and on the reimbursements from health insurance. The patient survey was conducted by university students from local cities and provinces. These students received training on interview skills and the contents of the questionnaire. Since this paper focuses on patients with health insurance coverage under the NCMS program, we excluded TB patients with other forms of health insurance schemes. As a result, we had 494 patients in our final sample.

In order to understand the medical costs and reimbursements of TB patients, we collected reimbursement data from January 2010 to December 2012 from the existing NCMS routine data system in each of the six counties. Eligible patients were identified via a TB diagnosis code from the information system. The reimbursement data contained information on the patient’s name, sex, age group, choice of health providers, hospitalization costs, and the reimbursement expenses.

In sum, quantitative data were collected from the TB patient database and the NCMS database. These two databases were complementary. On one hand, due to recall bias, TB patients may have exaggerated their medical expenses to highlight their economic burden and they were only able to remember their out-of-pocket (OOP) payments. The NCMS database, however, provided relatively accurate data about total and reimbursement expenses. On the other hand, medical expenditures beyond the NCMS reimbursement packages may have been excluded by the NCMS managers to report higher reimbursement rates for their counties. By comparing expenditures and reimbursement rates with the patient database, we were able to gain more detailed information. For these reasons, the effective reimbursement rates from the patient database were lower than those from medical expense records.

Qualitative study

FGDs were held with health care providers from the designated hospitals and TB patients. There were 6 groups each in both YC and HZ. Participants were selected with the help of the local CDCs. One FGD was organized with one stakeholder. The number of participants for each FGD was around 6–8.

The FGDs with the health care providers from the designated hospitals consisted of senior health administrators responsible for public health, heads of TB or infectious disease units, 2–3 chief consultants for TB care, heads of nursing from TB units or wards, and one senior and one junior nurse responsible for TB care. Issues posed included the financing and expenditure of TB care, provision of TB services, TB related health workforce and their income levels, etc.

As for FGDs with patients, inclusion criteria were patients with previous TB treatment experience who could clearly communicate their thoughts. Sex, age group, geographic location of residence, and socio-economic status were considered. Both new and relapsed TB patients were included in the group. Questions regarding their use of and experiences with health care, expenses and reimbursement related to TB care, and their subjective feelings about their financial burden and the usefulness of health insurance were asked.

A total of 12 FGDs were conducted by university faculty members. All FGDs were recorded under the permission of participants. In addition, health insurance policy documents related to the payment and reimbursement of TB treatment as well as provider payment methods were gathered from the study sites.

Definitions

In our study, total medical expenditure was composed of the actual amount received as reimbursement and any OOP payments. OOP payments were comprised of the expenses below the deductible, the expenses above the deductible which were co-paid by patients and the non-reimbursable amount which were beyond the NCMS benefit packages.

There were two major indicators to empirically measure the reimbursement level: the effective reimbursement rate and the non-reimbursable expenses rate. The effective reimbursement rate was the actual amount received as reimbursement divided by the total medical expenditure [23]. The non-reimbursable expenses rate was the non-reimbursable amount that were beyond the NCMS benefit packages divided by the total medical expenditure.

The definitions mentioned above are consistent with those used by the National Health and Family Planning Commission in China.

It is widely known that there is no commonly accepted criterion for defining CHE [24]. The criteria varies from 10 % of income [25, 26], 10 % of household consumption [27], to 40 % of disposable income [28, 29]. In this paper we regarded OOP health expenditures in excess of 10 % of annual family income as potentially catastrophic.

Analysis of the financial burden alleviation under the NCMS and the extent to which this resulted in catastrophic expenditure before and after receiving the NCMS reimbursement was also accomplished by counterfactual analysis. The state of the households after receiving reimbursement from the NCMS was factual; the state before households received reimbursement (as if they were not covered by the NCMS) was regarded as a counterfactual situation [30].

Two indicators were adapted: incidence and average gap of CHE. We hypothesized that health demand of TB patients would remain the same; then we proceeded to compare the incidence and average gap of CHE due to TB before and after the NCMS reimbursement. The incidence of CHE describes the frequency of households in six counties with health care costs as a share of total expenditure exceeding the chosen threshold in proportion to the sample [Eq. (1)]:
$$ \mathrm{C}\mathrm{HEI}={\displaystyle \sum \mathrm{C}\mathrm{I}/\mathrm{N}} $$
(1)

CHEI refers to the incidence of CHE. And CI is the catastrophe index. If a TB patient’s OOP payment as a proportion of their annual income is ≥10 %, then CI = 1; otherwise CI = 0. N is the total number of TB patients in the sample.

Average gap of CHE captures the severity of CHE. It describes how much a TB patient’s medical expenditure (as a percentage of their annual income) is in excess of the catastrophic threshold of 10 % of annual income [Eq. (2)]:
$$ \mathrm{A}\mathrm{G}={\displaystyle \sum \left(\mathrm{P}-10\%\right)/\mathrm{N}} $$
(2)

AG refers to the average gap of CHE. And P is the proportion of OOP cost as a percentage of the annual income of TB patients who incur CHE. N is the total number of TB patients in the sample.

The difference in CHE incidence and average gap before and after reimbursement reflects the impact of the NCMS.

Equity before and after the NCMS reimbursement was disaggregated by project sites and assessed by CI. Figure 1 presents the CI of CHE incidence rate. The CI is bounded between −1 and 1. For a discrete living standards variable, it can be written as
Fig. 1

Consideration index of CHE incidence

$$ CI=\frac{2}{N\mu }{\displaystyle {\sum}_{i=1}^N{h}_i{r}_i-1-\frac{1}{N}} $$

Where h i represents whether an individual suffers from CHE (yes = 1, no = 0), μ is its mean, and ri = i/N is the fractional rank of income, ranging from 0 to 1. For one individual ranked i, r_i = (i-0.5)/N, in which N is the total number of individuals. In this study, the CI was computed by the R programming language.

Data analysis

We used SPSS 17.0 to conduct the quantitative data analyses. The main analysis focused on the expenditure and reimbursement of TB related services. Chi-square tests were employed to identify differences in effective reimbursement rates between two research cities, and differences in the CHE incidences before and after NCMS reimbursement. P < 0.05 was considered to be statistically significant. Total expenses after diagnosis were analyzed to measure TB care reimbursement under the NCMS. In order to assess impact of the NCMS on TB financial burden alleviation, we used expenses throughout the treatment.

The resulting qualitative data were analyzed using thematic framework analysis [31]. Two researchers independently read through all transcripts and listed recruiting viewpoints relevant to questions in the interview guidelines. Codes were developed based on topic guides and the categories that emerged from the transcripts, and were applied to the data to identify themes. All qualitative data were coded, sorted and classified in terms of the analysis framework. Nvivo10 was used to manage the data. Charting was used to identify common or divergent perceptions and explanations were developed. Analysis was carried out in Chinese to keep information consistent and the final results were translated into English.

Documents concerning health insurance policies were also classified and analyzed by region using thematic framework analysis.

Quality assurance

All the data collection instruments, tools and procedures developed for the study were tested in a pilot exercise in one project city. Following this pilot exercise, a workshop was held to discuss any problems that arose and to identify appropriate modifications as required. A logic check of all the data collected was also undertaken to identify data gaps, inaccuracies, and apparent incongruities and inconsistencies.

The patient surveys were conducted by university students from local cities and provinces. These students were trained on interview skills and the contents of the questionnaire. All transcripts were cross-checked by different persons, allowing the identification and correction of any data entry errors.

The NCMS data from ZJ County were partly excluded due to errors in logic and only data from 2012 were included in the analysis.

Ethical approval

Ethical permission was obtained from the Institutional Ethics Committee, Chinese Center for Disease Control and Prevention, China.

Results

Demographics of TB patients

A total of 494 patients participated in the survey. There was a nearly even distribution within the six selected counties. The average age of the study sample was 54.69 years and about three-fourths of the sample were male. Over half of the participants had a primary school education or lower while 34.8 % completed secondary school and 11.3 % completed high school or higher. At 58.7 %, a majority of the participants were employed,30.8 % were retired, 0.1 % were retired but reemployed, 3.6 % were out of work, and 5.1 % were disabled. And the remaining were students or pre-school children. The average annual household income was 22795 yuan. These 494 patients were divided into three groups by household income. The average annual household incomes were 3552 yuan, 17429 yuan and 53560 yuan in the lower, median and upper quartiles, respectively (Table 1).
Table 1

Social-economic characteristics of TB patients (n = 494)

Category

Subcategory

Results (% (n))

Gender

Female

120 (24.30)

 

Male

374 (75.70)

Age

Age (Mean (SD))

54.69 (14.56)

Residence

YD

87 (17.60)

 

ZJ

80 (16.20)

 

WF

79 (16.00)

 

CG

84 (17.00)

 

MX

83 (16.80)

 

ZB

81 (16.40)

Marital

Married

394 (79.8)

 

Unmarried

35 (7.10)

 

Divorced

10 (2.00)

 

Widowed

55 (11.10)

Education

Primary school and lower

266 (53.80)

 

Secondary school or at the same level

172 (34.80)

 

High school and higher

56 (11.30)

Employment

Salaried job, farming or self-employment

290 (58.70)

 

The retired but reemployment

3 (0.06)

 

Unemployment

18 (3.60)

 

The retired

152 (30.80)

 

Disability

25 (5.10)

 

Student/pre-school children

6 (1.20)

Household income

Low (lowest 25)

133 (26.90)

(Missing = 3)

Middle (medium 50)

234 (47.40)

 

High (top 25)

124 (25.10)

Institutional background: The NCMS program in YC and HZ

Since the NCMS is decentralized and administered at the county level [16], we used the county as the unit for our analysis. From health insurance policy documents and FDGs, we gathered that general outpatient service and outpatient service reimbursement for selected catastrophic or chronic diseases existed in the NCMS outpatient reimbursement schemes. General outpatient service only reimburses medical fees for outpatients in primary-level medical and health care institutions, for example, village clinics and township health centers, at a certain proportion [32]. TB patients who must seek treatment in a county-level, TB designated hospital cannot claim reimbursement for general outpatient care. In 2009, the NCMS covered catastrophic or chronic outpatient costs in two-thirds of counties in China [33]. Outpatient service reimbursement for selected catastrophic or chronic diseases compensates large outpatient expenditures by establishing the catastrophic or chronic diseases pooling fund with separate deductibles and reimbursement caps. YC and HZ also developed different payment arrangements for outpatient care for specific catastrophic or chronic disease conditions, including TB. TB outpatient services can be reimbursed from pooled funds. Table 2 presents the reimbursement rules for TB outpatients under the NCMS by area.
Table 2

Reimbursement by the NCMS for TB outpatient care in 2012

 

Reimbursement rate or quota

Ceiling

YD

Quota subsidy 200 yuan/year

 

ZJ

Quota subsidy 45 yuan/month

540 yuan/year

WF

70 % of total annual expenditure

2000 yuan/year

CG

Quota subsidy 800 yuan/year

 

MX

80 % of total annual expenditure

1800 yuan/year

ZB

Quota subsidy

New patient ,2000 yuan/year;

Relapse patient, 2500 yuan/year

Data resource: Author’s data are collected from reimbursement policies of the NCMS offices

Reimbursement for TB inpatient services follows similar trends as other inpatient services in all the NCMS schemes. Inpatient deductibles are generally higher if patients receive treatment at higher level hospitals [34]; hence, the reimbursement rates decrease as the patients seek care at higher level hospitals. Table 3 shows the deductible and reimbursement rates, which indicates that the ceiling level for expense reimbursement ranges from RMB 100,000 to 150,000 yuan.
Table 3

Reimbursement by the NCMS for TB inpatient care in 2012

County

Deductible (Yuan)

Nominal reimbursement rate (%)

Township health centers

County hospitals

Municipal hospital

Township health centers

County hospitals

Municipal hospital

YD

100

500

500

85

65

50–65

ZJ

100

300

300–500

85

75

50–65

WF

50

200

500

80

70

55–65

CG

100–150

300–450

400–600

85–90

70–75

60–70

MX

100–150

300–550

350–550

85–90

75–80

60–70

ZB

100–150

300–550

400–550

80–90

70–80

60–70

Data resource: Author’s data are collected from reimbursement policies of the NCMS offices

TB care reimbursement under the NCMS

According to the NCMS database 1884 TB inpatients were reimbursed from 2010 to 2012 in YC and HZ, as shown in Table 4. The rates of non-reimbursable expenses accounted for 8.9 and 9.0 % of total inpatient expenses in YC and HZ, respectively. In addition, we divided OOP payments and the effective reimbursement rates by year. Given the reliability of data, only data in YD and WF were included (Figs. 2 and 3). These figures show the increase in effective reimbursement rates by year, while OOP payments showed no obvious decline.
Table 4

TB inpatient care reimbursement under the NCMS in YC and HZ from 2010 to 2012

County

Number

Total inpatient expenses (Yuan)

OOP (Yuan)

Rate of non- reimbursable expenses (%)

The effective reimbursement rate (%)

Mean

Median

Mean

Median

YD

430

4522

3106

2397

1513

7.8

47.0

ZJ

242

6372

4734

3048

1972

13.3

52.2

WF

329

4818

3148

2078

1195

5.8

56.9

Total

1001

5067

3602

2450

1609

8.9

51.6

CG

231

3878

3276

1730

1437

16.9

55.4

MX

233

4767

3907

1651

1376

13.7

65.4

ZB

419

4595

4131

1462

1281

2.7

68.2

Total

883

4453

3862

1582

1358

9.0

64.5

Data resource: Author’s data are collected from the NCMS database

Note: In YC, the NCMS data for three years are comprehensive with one exception of ZJ where only data in 2012 are included in the analysis. Given quality of data, data in MX and ZB in 2010 are excluded in the analysis

Fig. 2

OOP in YD and WF by year

Fig. 3

The effective reimbursement rate in YD and WF by year

Table 5 shows TB outpatient and inpatient care reimbursement under the NCMS in YC and HZ using the TB patient database. The effective reimbursement rate of TB inpatient care after diagnosis accounted for 51.9 and 45.9 % in YC and HZ, respectively. There was no statistically significant difference in the effective reimbursement rate for inpatient services between YC and HZ (P > 0.05).
Table 5

TB outpatient and inpatient care reimbursement after diagnosis under the NCMS in YC and HZ from 2010 to 2012

Area

Outpatient

Inpatient

Total Expenses (Yuan)

OOP (Yuan)

ERR (%)

Total Expenses (Yuan)

OOP (Yuan)

ERR (%)

YD

1379

1307

5.2

9086

3947

56.6

ZJ

1942

1903

2.0

14732

7535

48.9

WF

1032

938

9.1

13247

6143

53.6

Total

1490

1413

5.2

13562

6530

51.9

CG

486

451

7.2

11425

7636

33.2

MX

751

584

22.2

7410

3766

49.2

ZB

1189

276

76.8

6542

2619

60.0

Total

832

430

48.3

8234

4454

45.9

Data resource: Author’s data are collected from TB patient database

Note: ERR refers to “the effective reimbursement rate”

From the FGDs with doctors in designated hospitals, we found that TB inpatients were confronted with repeated treatment. We then analyzed service utilization of TB patients who were interviewed and found that 44.13 % of these patients received inpatient care. A majority of TB inpatients (92.13 %) were hospitalized in county or higher level hospitals for initial treatment after diagnosis. On the other hand, 17.13 % sought medical care in municipal hospitals, resulting in lower reimbursement rates. Patients’ repeated treatment and high hospitalization rates were caused by individual and health facility factors, according to the FGDs.

“TB patients receive low outpatient reimbursement rates. They prefer to be hospitalized, because they can claim higher reimbursement rates, and it is more comfortable and effective from their point of view. Some patients think, ‘At least I can get a general check-up.’”(Doctors in hospitals, FGDs)

“(The subsidy for doctors is insufficient), we make money by ourselves.” (TB doctors, FGDs)

“They (Doctors) have profit-seeking behavior.” (TB patients, FGDs)

Total outpatient expenses were near 1500 yuan after diagnosis in YC, and it was about 800 yuan in HZ (see Table 5). Outpatient expenses were high in certain counties, particularly in ZJ. The reimbursement level for TB outpatient care after diagnosis was very low. The effective reimbursement rate of TB outpatient care accounted for 5.2 and 48.3 % in YC and HZ, respectively. There were significant differences (P < 0.05) in effective reimbursement rate for outpatient treatment between YC and HZ. TB patients reflected that the reimbursement for TB outpatient care was limited effect.

As mentioned above, the NCMS covered a package of catastrophic or chronic disease-related services and TB was included in YC and HZ. But the reimbursement was based on a quota or was limited to a certain insured amount. TB outpatients had to pay all expenses above the quota out of pocket. In YD and ZJ, the quota levels for TB outpatient care were significantly lower than the corresponding outpatient expenses and that in HZ, resulting in lower reimbursement levels compared to counties in HZ. Moreover, reimbursement packages for TB outpatient care were less comprehensive than those for TB inpatient care. Outpatient reimbursement packages in most counties excluded many services covered by inpatient reimbursement packages, including CT scans, which further reduced the proportion of effective outpatient reimbursement.

“The reimbursement for outpatient care was low, and it had no effect. I only got reimbursed for 200 yuan. ” (TB patients, FGDs)

Impact of the NCMS on TB Financial Burden Alleviation

According to the Pearson’s chi square tests, there was no statistically significant difference in the CHE incidence before and after the NCMS reimbursement (P > 0.05), with the exception of MX (P = 0.035). Most catastrophic patients remained catastrophic; however, the average gap of CHE was reduced after TB patients were reimbursed from the NCMS, indicating a slight decline in the severity of CHE. The variation in average gap (Table 6) suggests that the reimbursement policies of the NCMS were effective in reducing CHE, but the impact was modest.
Table 6

Incidence and average gap of CHE, and concentration index of CHE incidence rate before and after the NCMS reimbursement by county

Counties

Incidence

Average gap

Concentration index

Pre-

Post-

Reduction

Pre-

Post-

Reduction

Pre-

Post-

Reduction

YD

52.0

48.0

4.0

20.9

15.3

5.6

−0.34

−0.30

−0.04

ZJ

85.7

85.7

0.0

76.8

55.4

21.4

−0.12

−0.12

0.00

WF

70.0

56.7

13.3

40.0

18.6

21.4

−0.16

−0.32

0.16

CG

73.4

68.8

4.6

131.2

77.8

53.4

−0.16

−0.20

0.04

MX

87.3

70.9

16.4

199.1

108.5

90.7

−0.07

−0.24

0.17

ZB

80.3

72.1

8.2

198.3

126.2

72.1

−0.15

−0.17

0.02

Note: “Reduction” refers to reduction by the NCMS. It indicates the difference before and after the NCMS reimbursement

The CI, our measure of equity, was negative for the NCMS reimbursement in all counties, indicating that in all cases CHE incidence rate was pro-poor. Poorer patients were particularly vulnerable, with high rates of catastrophic spending. But the absolute values of the CI for CHE incidence rate were all below 0.4, suggesting that equity was relatively reasonable. After the NCMS reimbursement, the harsh economic effects of TB on poorer populations were even worse, with the exception of YD.

Discussion

A review of studies that measured the economic costs of diseases, including TB, showed that low coverage and user charges led to high costs [35]. Pan HQ et al. interviewed 316 patients diagnosed from January 2010 to May 2011 who had already completed their anti-TB treatment in a cross-sectional survey, and found that the average per capita total OOP payment was 3024.0 yuan. They pointed out that the economic burden on patients was still heavy [36]. Long Q et al. found that low income patients paid a total of US$ 149 to 724 (RMB 1241 to 5228) for medical costs for a treatment course [37]. In 2011, the participation rate of NCMS was over 97 % [38]. A majority of TB patients in rural China can be covered by the NCMS, but as a government-subsidized rural health insurance, it mainly focuses on helping cover catastrophic medical expenses [39]. Its impact on the alleviation of the economic burden of TB remains to be seen. By accessing the effective reimbursement rates of the NCMS among TB patients, Wei X et al. found that the NCMS has not relieved the financial burden of TB-related medical costs; however, they focused on the TB dispensary approach.

Overall, our study revealed a mixed picture in terms of TB care reimbursement, and how the NCMS has influenced the level of financial burden and equity of TB patients under the integrated approach. More specifically, the study yielded four major findings.

We found that TB patients paid out of pocket for ancillary services, which were not covered by the NCMS [40], and revealed that TB outpatient care reimbursement remained inadequate. The quota subsidy for TB outpatient care led to inadequate outpatient reimbursement. Small TB outpatient expenditures may seem to be insignificant, but the annual cumulative amount maybe catastrophic. Yip and her colleagues pointed out that the NCMS does not address a major cause of medical impoverishment: expensive outpatient services for chronic conditions [41]. Disparities between inpatient and outpatient reimbursement policies possibly led to the high hospitalization rates for TB patients. The hospitalization costs were significantly higher, resulting in financial burden for TB patients. Thus, prevention of hospitalizations are needed [39].

We also found that effective reimbursement rates were far lower than the nominal reimbursement rates for inpatient care. There were three possible explanations for low reimbursement rates for TB inpatient care. First, TB patients had to be hospitalized at medical institutions at the county level or above. In our study, 92.13 % of patients were treated at county hospitals or higher, but reimbursement rules were typically less generous for TB patients hospitalized in higher level facilities. Large deductibles (ranging from 200 yuan to 500 yuan in YC and 300 yuan to 600 yuan in HZ) and high co-payments (ranging from 30 to 50 % in YC and 20 to 40 % in HZ) reduced the proportion of effective reimbursement. As a result, patients had to pay more OOP. Second, TB reimbursement packages were not comprehensive and certain expenses were excluded, including liver protection drugs. Take the medicine reimbursement list of Hubei province as an example – only eleven anti-TB items were included in the NCMS, including streptomycin, isoniazid, rifampicin, ethambutol, sodium aminosalicylate, pyrazinamide, rifapentine and rifamycin. Third, doctors in TB designated hospitals had strong financial incentives for excessive treatment under fee-for-service payment systems, including the use of second-line anti-TB drugs which were expensive and not included in reimbursement schemes. For example, the rate of non-reimbursable expenses accounted for 10.07 % of total medical expenditure in two cities.

The effective reimbursement rate for TB inpatient care has increased over the years, while the OOP payments have not. It appears that most of the reimbursement from the NCMS was offset by the growth of medical expenses [33], which was consistent with the analysis by Wagstaff et al. who found that the NCMS did not reduce OOP payments per outpatient visit or inpatient spell [22]. Financial burden experienced by TB patients can cause delays, low completion rates, poor adherence and drug resistance, as well as CHE and impoverishment [42, 43].

Reimbursement policy design for TB care led to differences in effective reimbursement rates between regions. Higher nominal reimbursement rates and ceilings for TB inpatient and outpatient care were offered in HZ when compared with YC, as shown in Tables 2 and 3. TB patients in HZ encountered lower medical expenditures and higher effective reimbursement rates, but the incidence and severity of CHE remained higher when compared with YC. This indicates that lower-income TB patients in resource-poor settings bear a heavier financial burden, which is in line with other studies [44, 45].

In YC, the reimbursement level for TB outpatient and inpatient care in ZJ was significantly lower than that in YD and WF, and medical expenses for outpatient and inpatient treatment were much higher. Thus, TB patients in ZJ incurred the highest OOP payments. Though the economic level of ZJ ranked in the middle of the three sample counties in YC, the incidence and severity of CHE remained the most serious. It shows that the main factors associated with the incidence and severity of CHE are medical expenditure and reimbursement level without considering other confounding factors.

TB patients paid a high proportion of medical care expenditure through OOP payments after the NCMS reimbursement. Poor TB patients incurred high rates of catastrophic spending due to inadequate reimbursement, in line with other studies which have found that the occurrence and intensity of CHE was greater among poor inpatients [10, 46, 47]; however, equity remained relatively reasonable. A possible explanation may be that the economically disadvantaged group constrained their essential health demand, which in turn is another avenue for further research.

We found the NCMS to be a protective factor in reducing the severity of CHE in particular, which was consistent with other studies [10, 18]. But the NCMS did not reduce the CHE incidence, with the exception of MX, due to inadequate outpatient and inpatient reimbursement levels, a finding that was in line with previous studies [44], and only the severity of CHE was relieved.

The equity of CHE incidence has not improved after the implementation of the NCMS. The effective reimbursement rate remains low under the NCMS, and since the program targets reimbursement for overall beneficiaries, equity improvement for TB patients is negatively affected.

Establishing the National Medical Financial Assistance Scheme (MFA) for the poor or disadvantaged may be effective in equity improvement. In 2003, the MFA was implemented in rural areas to assist, among others, poor and near-poor households facing high health care expenses [22]. Although the MFA was established across these six counties, the vast majority of TB patients could not meet the requirements to obtain the assistance services due to the strict admittance conditions.

Our study has its own limitations. First, since it was based on counterfactual analysis, the level of medical expenditures was assumed to be unchanged before and after NCMS reimbursement, while behavioral responses of patients and providers under reimbursement might have changed, which would have led to an increase in health expenditures. Thus, the impact of the NCMS on the alleviation of economic burden might be overestimated. This also reveals the fact that the NCMS has a modest impact on reducing the financial burden experienced by TB patients. Second, YC and HZ are two cities with different social and economic levels. Different reimbursement policies were employed. Thus, in order to eliminate confounding factors, comparisons were only made within each city.

Conclusion

This study examined the impact of the NCMS on TB care reimbursement and its effect on the financial burden of TB patients. A number of conclusions can be drawn from our findings. First, low reimbursement for TB outpatients and inpatients due to low reimbursement quotas led to heavy financial burdens on TB patients. Second, the effective reimbursement rates were lower than the reported nominal reimbursement rates for inpatient care. We also discovered a discrepancy between the lower effective reimbursement rates from the patient database and the higher rates from medical expense records. Third, poorer TB patients incurred higher rates of CHE, leaving lower income patients in a more vulnerable position despite the implementation of the NCMS. Fourth, the NCMS was found to be a protective factor for CHE, but the impact was modest. Furthermore, the equity of CHE did not improve after the NCMS reimbursement.

Our findings are valuable for policymakers to develop more effective interventions to relieve the financial burden of TB patients enrolling in the NCMS. The major policy implications from our study are twofold. First, increasing the reimbursement level for TB outpatients and reducing the variations in the reimbursement level across counties are two important avenues to alleviate the financial burden for TB patients and to increase the equity of health insurance systems. Second, since TB patients need to spend significant amounts of money on non-medical costs as well as on non-reimbursable medical costs during the treatment process, relying on a single policy tool such as health insurance coverage may not completely solve the problem of high financial burdens. A supplemental policy tool such as establishing an MFA program may be necessary to improve equity.

Abbreviations

CHE: 

catastrophic health expenditure

CI: 

concentration index

CG: 

Chenggu County

FGDs: 

focus group discussions

CDC: 

Center of Disease Control and Prevention

DOTS: 

directly observed treatment short course

HZ: 

Hanzhong City

MX: 

Mianxian County

MFA: 

the National Medical Financial Assistance Scheme

NCMS: 

New Cooperative Medical Scheme

OOP: 

out-of-pocket

TB: 

Tuberculosis

WF: 

Wufeng County

YC: 

Yichang City

YD: 

Yidu County

ZJ: 

Zhijiang County

ZB: 

Zhenba County

Declarations

Acknowledgements

The study upon which this paper was written is part of the large program entitled “China National Health and Family Planning Commission and the Gates Foundation TB Project” - a collaboration between the Government of China and the Melinda and Bill Gates Foundation (Grant No. 51914), and implemented by the China CDC. The Duke Global Health Institute, USA/Duke Kunshan University in China, and Nanjing Medical University, Huazhong University of Science and Technology and Xi’an Jiaotong University in China were contracted by the Foundation and China CDC to undertake the baseline survey, and monitoring and evaluation of innovative financial models of TB/MDRTB control and care in China. The authors would also like to express their deep appreciation to Prof. Chee-Ruey Hsieh in Global Health Research Center, Duke Kunshan University for his comments on the paper writing, and appreciation to all the staffs, teachers and students participating in the field study.This study was also supported by the project “Research on Economic Risk of Major Diseases and the Protection Effect Model of Rural Residents in the Central and Western Regions of China” (Grant No. 71203068), and the “Study on the Dynamic Optimization of Catastrophic Health Insurance Reimbursement Modes and the Scale of Fund Expenditure in the Perspective of UHC” (Grant No. 71573095), both supported by the National Natural Science Foundation of China.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine and Health Management, Huazhong University of Science and Technology
(2)
The Third Affiliated Hospital, Sun Yat-sen University
(3)
Hubei Provincial Center for Disease Control and Prevention
(4)
Shaanxi Provincial Institute for TB Control and Prevention
(5)
Duke Global Health Institute, Duke University
(6)
School of Public Health, Xi’an Jiaotong University
(7)
Global Health Research Center, Duke Kunshan University

References

  1. Wang L, Liu J, Chin DP. Progress in tuberculosis control and the evolving public-health system in China. Lancet. 2007;369(9562):691–6. doi:10.1016/S0140-6736(07)60316-X.View ArticlePubMedGoogle Scholar
  2. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238. doi:10.1371/journal.pmed.0040238.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Zhan S, Wang L, Yin A, Blas E. Revenue-driven in TB control—three cases in China. Int J Health Plann Manage. 2004;19(S1):S63–78.View ArticlePubMedGoogle Scholar
  4. Zhang T, Tang S, Jun G, Whitehead M. Persistent problems of access to appropriate, affordable TB services in rural China: experiences of different socio-economic groups. BMC Public Health. 2007;7:19. doi:10.1186/1471-2458-7-19.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Sun Q, Yin J, Yin X, Zou G, Liang M, Zhong J, et al. Does the integration of TB medical services in the general hospital improve the quality of TB care? Evidence from a case study in China. J Public Health. 2013;35(2):322–8. doi:10.1093/pubmed/fds089.View ArticleGoogle Scholar
  6. Wei X, Zou G, Walley J, Yin J, Lonnroth K, Uplekar M, et al. China tuberculosis policy at crucial crossroads: comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PLoS One. 2014;9(3):e90596. doi:10.1371/journal.pone.0090596.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Pan HQ, Bele S, Feng Y, Qiu SS, Lü JQ, Tang SW, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. Int J Tuberc Lung Dis. 2013;17(12):1575–80. 027–3719.View ArticlePubMedGoogle Scholar
  8. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763-75. Google Scholar
  9. Scheil‐Adlung X, Carrin G, Juetting J, Xu K. What is the impact of social health protection on access to health care, health expenditure and impoverishment? A comparative analysis of three African countries. 2006.Google Scholar
  10. Zhang L, Cheng X, Tolhurst R, Tang S, Liu X. How effectively can the New Cooperative Medical Scheme reduce catastrophic health expenditure for the poor and non‐poor in rural China? Trop Med Int Health. 2010;15(4):468–75.PubMedGoogle Scholar
  11. Ekman B. Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country. Health Policy. 2007;83(2):304–13.View ArticlePubMedGoogle Scholar
  12. Balaban V, Marks SM, Etkind SC, Katz DJ, Higashi J, Flood J, et al. Tuberculosis elimination efforts in the United States in the era of insurance expansion and the Affordable Care Act. Public Health Rep. 2015;130(4):349–54.PubMedGoogle Scholar
  13. Tang S. Tackling challenges of TB/MDRTB in China: concerted actions are imperative. Infect Dis Poverty. 2015;4:19. doi:10.1186/s40249-015-0050-4.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg HM, Venkatappa TK, Horsburgh CR, et al. Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis. 2015;19(1):31–8. doi:10.5588/ijtld.14.0373.View ArticlePubMedGoogle Scholar
  15. Li Y, Ehiri J, Tang S, Li D, Bian Y, Lin H, et al. Factors associated with patient, and diagnostic delays in Chinese TB patients: a systematic review and meta-analysis. BMC Med. 2013;11:156. doi:10.1186/1741-7015-11-156.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Babiarz KS, Miller G, Yi H, Zhang L, Rozelle S. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary health care: multivariate difference-in-difference analysis. Bmj. 2010;341(oct21 2):c5617-c5617.Google Scholar
  17. Chen Y, Jin GZ. Does health insurance coverage lead to better health and educational outcomes? Evidence from rural China. J Health Econ. 2012;31(1):1–14.View ArticlePubMedGoogle Scholar
  18. Jing S, Yin A, Shi L, Liu J. Whether New Cooperative Medical Schemes reduce the economic burden of chronic disease in rural China. PLoS One. 2013;8(1):e53062.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Lei X, Lin W. The new cooperative medical scheme in rural China: does more coverage mean more service and better health? Health Econ. 2009;18(S2):S25–46.View ArticlePubMedGoogle Scholar
  20. Liu D, Tsegai DW. The New Cooperative Medical Scheme (NCMS) and its implications for access to health care and medical expenditure: evidence from rural China. ZEF-Discussion Papers on Development Policy. 2011(155).Google Scholar
  21. Wei X, Zou G, Yin J, Walley J, Zhang X, Li R, et al. Effective reimbursement rates of the rural health insurance among uncomplicated tuberculosis patients in China. Trop Med Int Health. 2015;20(3):304–11. doi:10.1111/tmi.12438.View ArticlePubMedGoogle Scholar
  22. Wagstaff A, Lindelow M, Jun G, Ling X, Juncheng Q. Extending health insurance to the rural population: an impact evaluation of China’s new cooperative medical scheme. J Health Econ. 2009;28(1):1–19.View ArticlePubMedGoogle Scholar
  23. Yi H, Zhang L, Singer K, Rozelle S, Atlas S. Health insurance and catastrophic illness: a report on the New Cooperative Medical System in rural China. Health Econ. 2009;18 Suppl 2(S2):S119–27. doi:10.1002/hec.1510.View ArticlePubMedGoogle Scholar
  24. Heeley E, Anderson CS, Huang Y, Jan S, Li Y, Liu M, et al. Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke. 2009;40(6):2149–56.View ArticlePubMedGoogle Scholar
  25. McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic consequences for households of illness and of paying for health care in low-and middle-income country contexts? Soc Sci Med. 2006;62(4):858–65.View ArticlePubMedGoogle Scholar
  26. Ranson MK. Reduction of catastrophic health care expenditures by a community-based health insurance scheme in Gujarat, India: current experiences and challenges. Bull World Health Organ. 2002;80(8):613–21.PubMed CentralPubMedGoogle Scholar
  27. Limwattananon S, Tangcharoensathien V, Prakongsai P. Catastrophic and poverty impacts of health payments: results from national household surveys in Thailand. Bull World Health Organ. 2007;85(8):600–6.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. The lancet. 2003;362(9378):111–7.View ArticleGoogle Scholar
  29. Yardim MS, Cilingiroglu N, Yardim N. Catastrophic health expenditure and impoverishment in Turkey. Health Policy. 2010;94(1):26–33.View ArticlePubMedGoogle Scholar
  30. Sun X, Jackson S, Carmichael G, Sleigh AC. Catastrophic medical payment and financial protection in rural China: evidence from the New Cooperative Medical Scheme in Shandong Province. Health Econ. 2009;18(1):103–19.View ArticlePubMedGoogle Scholar
  31. Ruhl K. Qualitative Research Practice. A Guide for Social Science Students and Researchers. Journal of Advanced Nursing. 2004;60(6):708.Google Scholar
  32. Xiao H, Zhangkang Y. The analysis of the implementation of out-patient pooling funds of new Rural Cooperative Medical System in the mid and west area of rural China. Chinese Health Policy Res. 2009;2(5):45–50.Google Scholar
  33. Liang X, Guo H, Jin C, Peng X, Zhang X. The effect of new cooperative medical scheme on health outcomes and alleviating catastrophic health expenditure in China: a systematic review. PLoS One. 2012;7(8):e40850. doi:10.1371/journal.pone.0040850.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Barber SL, Yao L. Development and status of health insurance systems in China. Int J Health Plann Manage. 2011;26(4):339–56.View ArticlePubMedGoogle Scholar
  35. Breman JG, Alilio MS, Mills A, Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. 2004.Google Scholar
  36. Pan HQ, Bele S, Feng Y, Qiu SS, Lu JQ, Tang SW, et al. Analysis of the economic burden of diagnosis and treatment of tuberculosis patients in rural China. DiseaseInt J Tuberc Lung Dis. 2013;17(12):1575–80. doi:10.5588/ijtld.13.0144.View ArticleGoogle Scholar
  37. Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11:393. doi:10.1186/1471-2458-11-393.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Zhang L, Wang ZH, Qian DF, Ni J. Effects of changes in health insurance reimbursement level on outpatient service utilization of rural diabetics: evidence from Jiangsu Province, China. Bmc Health Serv Res. 2014;14. doi:10.1186/1472-6963-14-185.Google Scholar
  39. Liu Y. China’s public health-care system: facing the challenges. Bull World Health Organ. 2004;82(7):532–8.PubMed CentralPubMedGoogle Scholar
  40. Liu X, Thomson R, Gong Y, Zhao F, Squire SB, Tolhurst R, et al. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. Trop Med Int Health. 2007;12(12):1464–71.View ArticlePubMedGoogle Scholar
  41. Taylor Z, Marks S, Rios Burrows N, Weis S, Stricof R, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis. 2000;4(10):931–9.PubMedGoogle Scholar
  42. Laokri S, Drabo MK, Weil O, Kafando B, Dembele SM, Dujardin B. Patients are paying too much for tuberculosis: a direct cost-burden evaluation in Burkina Faso. PLoS One. 2013;8(2):e56752.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Long Q, Smith H, Zhang T, Tang S, Garner P. Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review. BMC Public Health. 2011;11(1):393.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Ayé R, Wyss K, Abdualimova H, Saidaliev S. Household costs of illness during different phases of tuberculosis treatment in Central Asia: a patient survey in Tajikistan. BMC Public Health. 2010;10(1):18.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Meng Q, Li R, Cheng G, Blas E. Provision and financial burden of TB services in a financially decentralized system: a case study from Shandong, China. Int J Health Plann Manage. 2004;19(S1):S45–62.View ArticlePubMedGoogle Scholar
  46. Arsenijevic J, Pavlova M, Groot W. Measuring the catastrophic and impoverishing effect of household health care spending in Serbia. Soc Sci Med. 2013;78:17–25.View ArticlePubMedGoogle Scholar
  47. Pal R. Measuring incidence of catastrophic out-of-pocket health expenditure: with application to India. Int J Health Care Finance Econ. 2012;12(1):63–85.View ArticlePubMedGoogle Scholar

Copyright

© Xiang et al. 2016